Johnson & Johnson disclosed that its 30‑patient, multi‑center OMNY‑AF pilot study achieved a 90% freedom from atrial fibrillation at 12 months, a benchmark that aligns with the company’s goal of establishing pulsed‑field ablation (PFA) as a competitive alternative to radiofrequency and cryoablation.
The study, presented at the 31st Annual AF Symposium, evaluated a novel pulsed‑field ablation platform that delivers non‑thermal, tissue‑selective energy. All 30 procedures were completed without any procedure‑related adverse events, and 56.7% of the cases were performed with zero fluoroscopy, underscoring the platform’s potential to reduce radiation exposure for both patients and clinicians.
These safety and efficacy results support Johnson & Johnson’s strategy to advance the OMNYPULSE platform toward regulatory submission and commercial launch. The company’s MedTech segment, which has been focused on high‑margin cardiovascular solutions, views the OMNY‑AF data as a key milestone that could broaden its electrophysiology portfolio and open new revenue streams in a rapidly growing PFA market.
Dr. Dinesh Sharma, the study’s presenting author, noted that the 12‑month data “provide encouraging early evidence on the OMNY‑AF study with promising safety outcomes – no procedure‑related adverse events or MRI‑detected cerebral lesions – across eight centers in the pilot phase.” Chief Medical and Scientific Officer Gregory Michaud added that the results “reinforce confidence in the consistency of safety outcomes observed across Johnson & Johnson’s electrophysiology portfolio” and highlighted the importance of rigorous evidence generation for advancing PFA technology.
Looking ahead, Johnson & Johnson plans to submit the data to regulatory authorities and pursue a commercial launch in the coming years. The company’s focus on integrating the OMNYPULSE platform with its CARTO 3 mapping system positions it to capture market share in a competitive landscape that includes Medtronic, Boston Scientific, and Abbott. The successful commercialization of OMNY‑AF could accelerate growth in the MedTech segment and strengthen J&J’s position as a leader in high‑growth cardiovascular solutions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.